You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 13, 2024

CLINICAL TRIALS PROFILE FOR OLANZAPINE AND FLUOXETINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Olanzapine And Fluoxetine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000373 ↗ Treatment of Obsessive-Compulsive Disorder Completed National Institute of Mental Health (NIMH) Phase 4 1992-09-01 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000373 ↗ Treatment of Obsessive-Compulsive Disorder Completed University of Florida Phase 4 1992-09-01 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00035321 ↗ The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression Completed Eli Lilly and Company Phase 3 2002-04-01 The purposes of this study are to determine: - Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression. - The safety of olanzapine plus fluoxetine in combination, plus and any side effects that might be associated with the combination. - The effectiveness of olanzapine plus fluoxetine compared to olanzapine and fluoxetine alone.
NCT00188942 ↗ A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder Completed Eli Lilly and Company Phase 4 2005-02-01 This study employs functional magnetic resonance imaging to compare brain activation patterns during a depressive episode in patients diagnosed with bipolar disorder, major depressive disorder, and a group of healthy control subjects. Depressed patients will be treated with a combination of fluoxetine and olanzapine and undergo MRI scans before, during, and after pharmacotherapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Olanzapine And Fluoxetine Hydrochloride

Condition Name

Condition Name for Olanzapine And Fluoxetine Hydrochloride
Intervention Trials
Bipolar Depression 4
Major Depressive Disorder 3
Treatment Resistant Depression 2
Bipolar Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Olanzapine And Fluoxetine Hydrochloride
Intervention Trials
Depression 13
Depressive Disorder 12
Bipolar Disorder 7
Depressive Disorder, Major 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Olanzapine And Fluoxetine Hydrochloride

Trials by Country

Trials by Country for Olanzapine And Fluoxetine Hydrochloride
Location Trials
United States 46
Canada 5
China 3
Russian Federation 2
Puerto Rico 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Olanzapine And Fluoxetine Hydrochloride
Location Trials
Pennsylvania 3
California 3
Massachusetts 3
Missouri 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Olanzapine And Fluoxetine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Olanzapine And Fluoxetine Hydrochloride
Clinical Trial Phase Trials
Phase 4 9
Phase 3 3
Phase 1/Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Olanzapine And Fluoxetine Hydrochloride
Clinical Trial Phase Trials
Completed 11
Recruiting 3
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Olanzapine And Fluoxetine Hydrochloride

Sponsor Name

Sponsor Name for Olanzapine And Fluoxetine Hydrochloride
Sponsor Trials
Eli Lilly and Company 7
National Alliance on Mental Illness Montana 1
University of Florida 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Olanzapine And Fluoxetine Hydrochloride
Sponsor Trials
Other 18
Industry 9
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.